Plant biotechnology is becoming an accepted avenue for pharmaceutical development. Researchers have engineered plants to grow biomolecules that can be made into therapeutics, including vaccines and monoclonal antibodies. These new technologies hold the promise of more readily bringing treatments to low-to-middle-income countries and providing rapid responses to future pandemics. In this episode, Niki Spahich from The Scientist's Creative Services Team spoke with Julian Ma, the director of the Institute for Infection and Immunity and professor of molecular immunology at St. George’s Hospital Medical School, to learn more.
The Scientist Speaks is a podcast produced by The Scientist’s Creative Services Team. Our podcast is by scientists and for scientists. Once a month, we bring you the stories behind news-worthy molecular biology research. This month's episode is sponsored by Daicel Arbor Biosciences.
Julian Ma, PhD Hotung Chair, Molecular Immunology Director, Institute for Infection and Immunity St George's Hospital Medical School
Daicel Arbor Biosciences is a biotech company that specializes in targeted next generation sequencing (NGS), in situ hybridization probe design, and cell-free protein expression. They have served their customers in plant genetics, microbiology, agriculture, archaeology, oncology, and genetic diseases areas for more than fifteen years.
TS_Podcast_TSS_From Plants to Therapeutics
Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this podcast. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these podcasts free of charge for our readers.
The Scientist c/o LabX Media Group 1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801 Toll Free: 888.788.0328 | Phone: 705.528.6888 Email: email@example.com